Fibromun is an anti-cancer immunotherapy

Sun Pharmaceutical Industries and Philogen have entered into a global licensing agreement for commercialising Philogen’s speciality product, Fibromun (L19TNF). Fibromun, an innovative anti-cancer immunotherapy, is being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma.

Under the terms of the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun. Philogen will complete the ongoing pivotal clinical trials for the product, pursue Marketing Authorization with regulatory authorities, and manufacture commercial supplies. Sun Pharma will be responsible for commercialisation activities. The two partner companies will share post-commercialization economics in about 45(Philogen):55(Sun Pharma) ratio. Other financial terms were not disclosed.

Dilip Shanghvi, CMD, Sun Pharma, said, “Fibromun’s progress through development has been quite encouraging and it has the potential to be an important option for the treatment of soft-tissue sarcomas and other cancers with significant unmet medical needs. This partnership expands our clinical pipeline into oncology in alignment with our current portfolio in skin cancers. We keenly look forward to providing this treatment option globally in due course of time.”

Prof Dr Dario Neri, CEO and CSO, Philogen, commented, “We are pleased to extend our collaboration with Sun Pharma, a leading global pharmaceutical company, from our existing partnership on Nidlegy to Fibromun. The collaboration will focus on the global commercialisation of Fibromun, a new immunotherapy that has the potential to serve patients with soft tissue sarcoma and certain malignant forms of brain tumours (e.g., glioblastoma), for which limited therapeutic alternatives exist."